Labelled prostate-specific membrane antigen (PSMA) in PET-CT fusion (PSMA PET-CT) was superior in specificity and sensitivity to conventional imaging in pre-treatment staging of intermediate- and high-risk localised prostate cancer.
Prof. Michael Hofman (Peter MacCallum Cancer Centre, Australia) presented the results of the ProPSMA study, which was recently also published in The Lancet [1,2]. The rationale of the study was that pre-treatment staging of intermediate- and high-risk localised prostate cancer is important for treatment choice, yet current standard imaging has limited sensitivity. The study investigated whether imaging using PSMA PET-CT was superior to conventional imaging in pre-treatment staging.
Men with histologically confirmed prostate cancer who were being considered for curative-intent radical prostatectomy or radiotherapy (n=302) were randomly alloc...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Prostatectomy: R-LRPE better than LRPE for continence Next Article
Docetaxel + hormonal therapy: improved prostate cancer PFS »
Table of Contents: EAU 2020
Surgical Techniques and Safety
Prostate Cancer & Imaging
BPH & LUTS
Testis Cancer & Andrology
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.